Olink Holding AB (OLK)
23.94
-0.01
(-0.04%)
USD |
NASDAQ |
May 17, 16:00
23.94
0.00 (0.00%)
After-Hours: 20:00
Olink Enterprise Value: 2.869B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 2.869B |
May 16, 2024 | 2.869B |
May 15, 2024 | 2.876B |
May 14, 2024 | 2.840B |
May 13, 2024 | 2.814B |
May 10, 2024 | 2.790B |
May 09, 2024 | 2.800B |
May 08, 2024 | 2.809B |
May 07, 2024 | 2.778B |
May 06, 2024 | 2.769B |
May 03, 2024 | 2.752B |
May 02, 2024 | 2.753B |
May 01, 2024 | 2.711B |
April 30, 2024 | 2.754B |
April 29, 2024 | 2.794B |
April 26, 2024 | 2.731B |
April 25, 2024 | 2.759B |
April 24, 2024 | 2.680B |
April 23, 2024 | 2.651B |
April 22, 2024 | 2.630B |
April 19, 2024 | 2.610B |
April 18, 2024 | 2.660B |
April 17, 2024 | 2.662B |
April 16, 2024 | 2.708B |
April 15, 2024 | 2.718B |
Date | Value |
---|---|
April 12, 2024 | 2.728B |
April 11, 2024 | 2.754B |
April 10, 2024 | 2.774B |
April 09, 2024 | 2.769B |
April 08, 2024 | 2.780B |
April 05, 2024 | 2.784B |
April 04, 2024 | 2.800B |
April 03, 2024 | 2.825B |
April 02, 2024 | 2.812B |
April 01, 2024 | 2.813B |
March 31, 2024 | 2.814B |
March 28, 2024 | 2.802B |
March 27, 2024 | 2.814B |
March 26, 2024 | 2.871B |
March 25, 2024 | 2.917B |
March 22, 2024 | 2.902B |
March 21, 2024 | 2.871B |
March 20, 2024 | 2.887B |
March 19, 2024 | 2.882B |
March 18, 2024 | 2.877B |
March 15, 2024 | 2.855B |
March 14, 2024 | 2.857B |
March 13, 2024 | 2.857B |
March 12, 2024 | 2.838B |
March 11, 2024 | 2.835B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
953.00M
Minimum
Jun 14 2022
4.510B
Maximum
Apr 27 2021
2.536B
Average
2.552B
Median
Apr 21 2023
Enterprise Value Benchmarks
Thermo Fisher Scientific Inc | 255.70B |
Abliva AB | 7.716M |
Karolinska Development AB | 62.17M |
Calliditas Therapeutics AB | 592.09M |
Oncopeptides AB | 12.46M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -16.06M |
Revenue (Quarterly) | 28.75M |
Total Expenses (Quarterly) | 53.69M |
EPS Diluted (Quarterly) | -0.13 |
Gross Profit Margin (Quarterly) | 60.68% |
Profit Margin (Quarterly) | -55.87% |
Earnings Yield | -1.13% |
Normalized Earnings Yield | -1.351 |